Company and Industry Summary Company Overview - **Company**: 海普瑞 (Haiprui) - **Industry**: Pharmaceutical Key Financial Metrics - **2025 Net Profit**: 4.2 billion RMB, up 66.1% year-on-year; excluding investment impairment, core net profit is 5 billion RMB [2][3] - **Operating Cash Flow**: 17.1 billion RMB, indicating significant financial structure optimization [2] - **Revenue**: 54.8 billion RMB, a 3.8% increase year-on-year [3] - **Debt Ratio**: Reduced to 27.4%, with interest expenses down 49.4% [3] Business Segments Performance Formulation Business - **Revenue**: 35.1 billion RMB, up 17.5%, accounting for 64% of total revenue [4] - **Sales Volume**: 290 million units, a historical high, with a 25% increase [4] - **Market Position**: First in national procurement in China, successful bids in multiple European countries, aiming for a 40% global market share [2][4] API Business - **Revenue**: 8 billion RMB, down 25.2% due to industry price declines [4] - **Gross Margin**: Dropped to 15.7%, a decrease of 13.6 percentage points [4] - **Market Dynamics**: Industry export prices fell approximately 20%, with the company maintaining better pricing than the industry average [4][7] CDMO Business - **Revenue**: 10.3 billion RMB, stable year-on-year [4] - **Gross Margin**: Increased to 36.4%, close to historical highs [4] Strategic Directions for 2026 1. **Strengthening Formulation Business**: Focus on overseas markets and deepening market penetration [3] 2. **Expanding Innovative Business**: Increase CMO business and leverage global sales channels for CSO business [3] 3. **Enhancing Financial Management**: Optimize asset-liability structure and improve capital efficiency [3] Investment and Risk Management - **Investment Impact**: 2025 saw a negative impact of approximately 2.5 billion RMB from investment projects, primarily due to RVS project impairments [5] - **Future Risks**: RVS project impairment risk is low moving forward, with remaining balance at 30 million RMB [5] Production Capacity and Efficiency - **New Facility**: The Pingshan factory has a total capacity of 550 million units, with an expected surplus of 200 million units by 2026 [2][6] - **Depreciation**: Estimated at 50 million RMB annually, with minimal impact on overall gross margin [6] Market Trends and Outlook - **European Market**: Expected to continue growing, with strategies to maintain pricing levels while exploring new markets [12][13] - **Chinese Market**: Anticipated further growth, with a market share increase from 20%-30% to approximately 40% [13][16] - **Non-European Markets**: Rapid growth expected, with significant opportunities for expansion [13] Currency and Financial Risk Management - **Hedging Strategies**: The company employs hedging to mitigate currency fluctuation risks, ensuring financial stability [17] Long-term Vision - **Future Development**: The company aims to become an innovative international enterprise, continuing to invest in R&D while leveraging existing strengths in the heparin industry [14][15][18]

Investment Rating - The report maintains a positive outlook on WuXi AppTec, indicating a strong growth trajectory and a valuation reset [4]. Core Insights - WuXi AppTec's Q4 2025 performance aligns with earnings forecasts, with total revenue growth projected at 13-17% and sustainable business revenue growth at 18-22% for 2026, despite geopolitical uncertainties [4]. - The company has shown robust order momentum, with new orders in Q4 2025 increasing by 29% year-over-year, and TIDES orders accelerating from 17% to 20% growth [4][5]. - The recent stock price pullback is viewed as an opportunity for investment, as the increasing share of CMO (Contract Manufacturing Organization) business reduces sensitivity to interest rate changes and biotech financing [5]. Summary by Sections Company Overview - WuXi AppTec operates globally across Asia, Europe, and North America, providing comprehensive R&D and manufacturing services to advance the pharmaceutical and healthcare industries [10]. - The company covers the entire R&D cycle through five core business segments: small molecule R&D and manufacturing, biologics R&D and manufacturing, cell and gene therapy R&D and manufacturing, medical device testing, and molecular diagnostics and genomics [10]. Revenue Breakdown - Revenue by product category: Chemical business (72.3%), Testing business (16.2%), Biological business (6.3%), High-end therapeutic CTDMO (3.2%) [11]. - Revenue by region: Middle East and Africa (8.7%), Asia (36.5%), Europe (27.3%), Americas (27.5%) [11]. Growth Drivers - The overall order growth rate of 29% in Q4 2025 surpasses the TIDES order growth rate of 20%, suggesting a more balanced growth driver for 2026-27 [7]. - The number of CMO projects is expected to increase from 72 in Q4 2024 to 83 in Q4 2025, maintaining global competitiveness despite local supply chain trends [6]. Catalysts - Recent stock price fluctuations have enhanced valuation attractiveness, creating favorable investment opportunities [8].

Group 1: Financial Performance - The company achieved a revenue of 1.384 billion CNY, a year-on-year decrease of 2.60% [1] - The net profit attributable to shareholders was 89 million CNY, down 20.70% year-on-year [1] Group 2: Business Segment Performance - The nuclear medicine segment generated sales of 503 million CNY, a year-on-year increase of 0.78% [2] - Key product 18F-FDG sales reached 212 million CNY, up 8.72% due to increased sales volume [2] - Yunk injection sales were 116 million CNY, down 5.69% [2] - Iodine-125 sealed source sales were 70.89 million CNY, down 8.34% [2] - The raw material drug segment reported sales of 611 million CNY, a year-on-year decrease of 7.02% [2] - Heparin raw material sales were 440 million CNY, down 8.90% due to price declines [2] - Glucosamine sulfate sales were 165 million CNY, up 4.26% [2] - The formulation segment achieved sales of 182 million CNY, a year-on-year increase of 1.76% [2] Group 3: Research and Development - R&D expenses for the first half of 2025 totaled 121 million CNY, with 94.75 million CNY being expensed and 26.39 million CNY capitalized [10] - Ongoing clinical trials include: - 18F-SR peptide injection in Phase III [2] - 18F-alpha peptide injection in Phase III [2] - 18F-fibrin inhibitor and 177Lu-LNC1011 in Phase II [2] Group 4: Market and Regulatory Developments - 27 provinces and regions in China have issued medical service price lists, separating examination fees from drug costs, which is expected to boost FDG sales [4] - The company’s products, including Technetium-99m and Fluorine-18, are included in the 2025 medical insurance preliminary review directory, with negotiations expected to conclude in November [6] Group 5: Production Capacity and Infrastructure - The company operates 7 single-photon and 22 positron emission nuclear medicine production centers, with 31 centers in total, covering 93.5% of the domestic nuclear medicine demand [3] - The production center network is a core competitive advantage for the company [3] Group 6: Future Prospects and Strategic Directions - The company is exploring the combination of nuclear medicine with other treatment methods due to the complexity of tumors [15] - New targeted therapies are under development, including those targeting FAP and somatostatin receptors [16]